[HTML][HTML] Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib …
AL Cheng, Z Guan, Z Chen, CJ Tsao, S Qin… - European Journal of …, 2012 - Elsevier
BACKGROUND: The phase III Sorafenib Asia–Pacific (AP) trial—conducted in China,
Taiwan and South Korea–confirmed that sorafenib improves overall survival (OS) and is …
Taiwan and South Korea–confirmed that sorafenib improves overall survival (OS) and is …
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia …
AL Cheng, Z Guan, Z Chen, CJ Tsao, S Qin… - European Journal of …, 2012 - ejcancer.com
Abstract Background The phase III Sorafenib Asia–Pacific (AP) trial—conducted in China,
Taiwan and South Korea–confirmed that sorafenib improves overall survival (OS) and is …
Taiwan and South Korea–confirmed that sorafenib improves overall survival (OS) and is …
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia …
AL Cheng, Z Guan, Z Chen, CJ Tsao… - EUROPEAN …, 2012 - scholar.korea.ac.kr
Background: The phase III Sorafenib Asia-Pacific (AP) trial-conducted in China, Taiwan and
South Korea-confirmed that sorafenib improves overall survival (OS) and is safe for patients …
South Korea-confirmed that sorafenib improves overall survival (OS) and is safe for patients …
[引用][C] Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib …
AL CHENG, Z GUAN, J XU, F FANG… - European journal of …, 2012 - pascal-francis.inist.fr
Author CHENG, Ann-Lii 1; ZHONGZHEN GUAN 2; JIANMING XU 11; FANG FANG 12; ZOU,
Jessie 12; LENTINI, Giuseppe 13; VOLIOTIS, Dimitris 12; KANG, Yoon-Koo 14; ZHENDONG …
Jessie 12; LENTINI, Giuseppe 13; VOLIOTIS, Dimitris 12; KANG, Yoon-Koo 14; ZHENDONG …
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia …
AL Cheng, Z Guan, Z Chen, CJ Tsao, S Qin… - European Journal of …, 2012 - pure.korea.ac.kr
Background: The phase III Sorafenib Asia-Pacific (AP) trial-conducted in China, Taiwan and
South Korea-confirmed that sorafenib improves overall survival (OS) and is safe for patients …
South Korea-confirmed that sorafenib improves overall survival (OS) and is safe for patients …
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia …
AL Cheng, Z Guan, Z Chen, CJ Tsao, S Qin… - European Journal of …, 2012 - infona.pl
The phase III Sorafenib Asia–Pacific (AP) trial—conducted in China, Taiwan and South
Korea–confirmed that sorafenib improves overall survival (OS) and is safe for patients with …
Korea–confirmed that sorafenib improves overall survival (OS) and is safe for patients with …
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia …
AL Cheng, Z Guan, Z Chen, CJ Tsao, S Qin… - European Journal of …, 2012 - europepmc.org
Background The phase III Sorafenib Asia-Pacific (AP) trial-conducted in China, Taiwan and
South Korea-confirmed that sorafenib improves overall survival (OS) and is safe for patients …
South Korea-confirmed that sorafenib improves overall survival (OS) and is safe for patients …
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia …
AL Cheng, Z Guan, Z Chen, CJ Tsao… - … journal of cancer …, 2012 - pubmed.ncbi.nlm.nih.gov
Background The phase III Sorafenib Asia-Pacific (AP) trial-conducted in China, Taiwan and
South Korea-confirmed that sorafenib improves overall survival (OS) and is safe for patients …
South Korea-confirmed that sorafenib improves overall survival (OS) and is safe for patients …
[引用][C] Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib …
AL Cheng, Z Guan, Z Chen, CJ Tsao, S Qin… - European Journal of …, 2012 - cir.nii.ac.jp
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according
to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial | CiNii …
to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial | CiNii …
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia …
AL Cheng, Z Guan, Z Chen, CJ Tsao, S Qin… - European Journal of …, 2012 - infona.pl
The phase III Sorafenib Asia–Pacific (AP) trial—conducted in China, Taiwan and South
Korea–confirmed that sorafenib improves overall survival (OS) and is safe for patients with …
Korea–confirmed that sorafenib improves overall survival (OS) and is safe for patients with …